• Dr. Reddy’s li­censed to sell vol­ume-limited amounts of ge­ner­ic lena­lido­mide in the U.S. be­gin­ning on a con­fi­den­tial date after the March 2022 date pre­vi­ously granted to Natco
• Dr. Reddy’s also li­censed to sell ge­ner­ic lena­lido­mide in the U.S. without vol­ume lim­i­ta­tion be­gin­ning on Jan­u­ary 31, 2026
• The earliest li­censed entry of any ge­ner­ic lena­lido­mide in the U.S. con­tinues to be March 2022, based on set­tle­ments reached

New York, NY (Press Release) – Bristol Myers Squibb (NYSE:BMY) to­day an­nounced that its wholly owned sub­sid­i­ary, Celgene, and Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, DRL) have set­tled their lit­i­ga­tion re­lated to pat­ents for REVLIMID® (lena­lido­mide).

As part of the set­tle­ment, the parties will file Consent Judgments with the United States District Court for the District of New Jersey that enjoin DRL from mar­ket­ing ge­ner­ic lena­lido­mide be­fore the expiration of the pat­ents-in-suit, except as provided for in the set­tle­ment, …

New York, NY (Press Release) – Cytovia Thera­peutics, an emerging bio­pharma­ceu­tical com­pany and the New York Stem Cell Foundation (NYSCF) Re­search in­sti­tute to­day an­nounced the filing of a provisional pat­ent appli­ca­tion with the U.S. Patent & Trade­mark Office (USPTO) for the dif­fer­en­tiation of Natural Killer (NK) cells from induced pluripotent stem cells (iPSCs). The NYSCF Re­search In­sti­tute is a pio­neer and acknowledged leader in stem cell tech­nology, having devel­oped the NYSCF Global Stem Cell Array®, the premier automated robotic plat­form for reprogramming skin or blood into induced pluripotent stem cells (iPSCs) and dif­fer­en­tiating …

New York, NY (Press Release) – Phosplatin Thera­peutics LLC, a clin­i­cal stage pharma­ceu­tical com­pany focused on on­col­ogy thera­peutics, to­day an­nounced that the United States Patent and Trade­mark Office (USPTO) has issued US Patent No. 10,668,080, entitled: "Phosphaplatin Compounds as Thera­peutics Agents for Treatment of Bone or Blood Cancers." The granted claims are directed to the use of (pyrophosphato)platinum(II) or (pyrophosphato)platinum(IV) complexes, in­clu­sive of the Com­pany's lead com­pound, PT-112, as thera­peutic agents for the treat­ment of bone and blood can­cers, such as mul­ti­ple myeloma, or solid tumor can­cers that metastasize to bone, such as …

Covers composition of mat­ter and method of use into 2036 for pro­pri­e­tary PLE analogs in com­bi­na­tion with var­i­ous small mol­e­cule chemo­ther­a­peu­tics

Florham Park, NJ (Press Release) – Cellectar Bio­sciences, Inc. (NASDAQ: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, de­vel­op­ment and com­mer­cial­i­za­tion of drugs for the treat­ment of cancer, to­day an­nounced that the Euro­pean Patent Office has an­nounced the intent to grant pat­ent num­ber EP3229810 (B1) titled “Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles.” The pat­ent provides composition of mat­ter and use pro­tec­tion for the com­pany’s pro­pri­e­tary PLE, targeted de­livery vehicle analogs in com­bi­na­tion with a broad range of chemo­ther­a­peu­tics such as paclitaxel, gemcitabine, and other classes of small mol­e­cule chemo­ther­a­peu­tic …

Patent covers the phos­pho­lipid ether (PLE) de­livery vehicle com­bined with I-131 and I-125

Florham Park, NJ (Press Release) – Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, de­vel­op­ment and com­mer­cial­iza­tion of drugs for the treat­ment of cancer, to­day an­nounced that the Euro­pean Patent Office has granted pat­ent num­ber EP 2440253 titled “Ether and Alkyl Phospholipid Compounds for Treating Cancer and Imaging and Detection of Cancer Stem Cells." The pat­ent provides composition of mat­ter and use pro­tec­tion for the treat­ment and/or diag­nosis of cancer and cancer stem cells for the com­pany’s Phase 2 lead asset CLR 131 and the pro­pri­e­tary PLE analogs …

Thousand Oaks, CA (Press Release) – Amgen (NASDAQ:AMGN) to­day an­nounced that the U.S. District Court in Delaware issued a de­ci­sion upholding the validity of pat­ent claims from three pat­ents that pro­tect Amgen's multiple myeloma ther­apy KYPROLIS® (car­filz­o­mib). Today's de­ci­sion will prevent Cipla Limited, and Cipla USA, Inc. (collectively "Cipla") from making, using, selling, offering to sell, or importing its generic version of KYPROLIS until expiration of these three U.S. pat­ents. The latest pat­ent expiry is in De­cem­ber 2027.

Onyx Thera­peutics, Inc., an indirect, wholly-owned sub­sid­i­ary of Amgen Inc., brought a pat­ent in­fringe­ment suit …

New York, NY (Press Release) – Starton Thera­peutics Inc. (“Starton” or the “Com­pany”), a bio­technol­ogy com­pany focused on trans­forming standard of care thera­peutics, to­day an­nounced that it has filed PCT (“Patent Cooperation Treaty”) and US Non-Provisional pat­ent appli­ca­tions entitled “Continuous Delivery of Lena­lido­mide and Other Immuno­modu­la­tory Agents” on April 21, 2020 (PCT Appli­ca­tion No. PCT/US20/29159 and U.S. Appli­ca­tion No. 16/854,810).

The PCT appli­ca­tion, filed with the PCT re­ceiv­ing office at the U.S. Patent & Trademark Office, allows Starton to file pat­ent appli­ca­tions to seek pro­tec­tion for the methods disclosed therein in most major …